Dallas, TX., , Oct. 04, 2017 (GLOBE NEWSWIRE) -- William A. Hartman, CEO of Premier Biomedical Inc. (OTCQB:BIEI) interviewed on the Uptick Network Stock Day Podcast with host Everett Jolly. Mr. Hartman provided updates on the upgraded hemp pain relief products, and explained the final resolution of the production issues. Mr. Hartman discussed the Biologics Division of PBI’s cancer project and their hiring a reputable agent to help develop potential partners for this Division. Mr. Hartman briefly touched on the potential of a major sales marketing meeting held recently that may revolutionize PBI’s entire marketing strategy. Furthermore, Mr. Hartman provided updates on PBI’s marketing strategies with new and updated contracts to continue awareness of the stock.
Mr. Hartman stated, “We are aware that a lot of people would lose money if they sold their holdings today. My recommendation is to hold on and see the big picture. We finally have revenue producing products that are peaking at the perfect time. Our anti-pain products are all-natural, pesticide and solvent free, non-GMO, drug test safe without any known side effects that relieve pain of all kinds;” continuing, Mr. Hartman stated, “We think that we have the perfect product at this time. People are very conscious about their health and the dangers of opioid poisoning, and we have a series of products that can in fact help eliminate their use of opioids. My advice to the stock holders is to hang on. This is not a sprint, this is a marathon and I think the marketing discussion that happened this past Saturday was the most exciting meeting that I've had with this company in many years.”
To listen to the full interview please click here or the following link: https://upticknewswire.com/featured-interview-ceo-william-hartman-of-premier-biomedical-inc-otcqb-biei-sept-update
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” For more information please visit our website: http://www.premierbiomedical.com.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
Source: Uptick Newswire